Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mean free path and Mean free time01:22

Mean free path and Mean free time

5.1K
Consider the gas molecules in a cylinder. They move in a random motion as they collide with each other and change speed and direction. The average of all the path lengths between collisions is known as the "mean free path."
5.1K
Path Between Thermodynamics States01:21

Path Between Thermodynamics States

4.0K
Consider the two thermodynamic processes involving an ideal gas that are represented by paths AC and ABC in Figure 1:
4.0K
Interference: Path Lengths01:10

Interference: Path Lengths

2.2K
Consider two sources of sound, that may or may not be in phase, emitting waves at a single frequency, and consider the frequencies to be the same.
Two special sources may be considered when they are in phase. This can be easily achieved by feeding the two sources from the same source. An example would be synchronizing the two speakers by feeding them with the same source, such as the sound waves produced by a tuning fork. This setup ensures that the two sources have the same frequency and are...
2.2K
Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion03:48

Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion

31.3K
Although gaseous molecules travel at tremendous speeds (hundreds of meters per second), they collide with other gaseous molecules and travel in many different directions before reaching the desired target. At room temperature, a gaseous molecule will experience billions of collisions per second. The mean free path is the average distance a molecule travels between collisions. The mean free path increases with decreasing pressure; in general, the mean free path for a gaseous molecule will be...
31.3K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.1K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Emulation Falls Short: Reaffirming the Role of Randomized Clinical Trials.

Circulation. Population health and outcomes·2026
Same author

Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Early Discontinuation of Long-Term Anticoagulation After Surgical Left Atrial Appendage Occlusion.

The Annals of thoracic surgery·2026
Same author

Enrollment of Older Patients, Women, and Historically Underrepresented Racial and Ethnic Groups in Pulmonary Embolism Trials: A Systematic Review.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Enrollment of Historically Underrepresented Groups in Peripheral Arterial Disease Trials: A Systematic Review.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

REPLY: Next Steps for Studying Behaviorally Designed Gamification to Increase Physical Activity.

JACC. CardioOncology·2026
Same journal

SBK2 Links Cardiac Stress Signaling to Mitochondrial Proteostasis.

Circulation research·2026
Same journal

Myeloid Piezo1 as a Brake on Efferocytosis and Cardiac Repair in the Infarcted Heart.

Circulation research·2026
Same journal

Targeting Late Na<sup>+</sup> Current: Too Late or Better Late Than Never?

Circulation research·2026
Same journal

HFpEF-Any: Human Single-Nuclear Transcriptomics Challenging the Translational Validity of Current HFpEF Models.

Circulation research·2026
Same journal

Myovascular Niche: The Role of Endothelial Cells in Skeletal Muscle Health and Disease.

Circulation research·2026
Same journal

Meet the First Authors.

Circulation research·2026
See all related articles

Related Experiment Video

Updated: Feb 3, 2026

Harmonic Nanoparticles for Regenerative Research
09:23

Harmonic Nanoparticles for Regenerative Research

Published on: May 1, 2014

12.1K

A Path Forward for Regenerative Medicine.

Alexander C Fanaroff1,2, Valarie Morrow2, Mitchell W Krucoff1,2

  • 1From the Division of Cardiology (A.C.F., M.W.K., T.J.P.).

Circulation Research
|October 26, 2018
PubMed
Summary
This summary is machine-generated.

Regulatory approval for cardiovascular cell therapies faces challenges in manufacturing, trial design, and efficacy demonstration. Strategies include data sharing networks, innovative endpoints, and early regulatory engagement to advance regenerative medicine.

Keywords:
United States Food and Drug Administrationcell transplantationdrug approvalregenerative medicineregistries

More Related Videos

20 mJ, 1 ps Yb:YAG Thin-disk Regenerative Amplifier
10:17

20 mJ, 1 ps Yb:YAG Thin-disk Regenerative Amplifier

Published on: July 12, 2017

12.0K
Foraging Path-length Protocol for Drosophila melanogaster Larvae
07:26

Foraging Path-length Protocol for Drosophila melanogaster Larvae

Published on: April 23, 2016

9.9K

Related Experiment Videos

Last Updated: Feb 3, 2026

Harmonic Nanoparticles for Regenerative Research
09:23

Harmonic Nanoparticles for Regenerative Research

Published on: May 1, 2014

12.1K
20 mJ, 1 ps Yb:YAG Thin-disk Regenerative Amplifier
10:17

20 mJ, 1 ps Yb:YAG Thin-disk Regenerative Amplifier

Published on: July 12, 2017

12.0K
Foraging Path-length Protocol for Drosophila melanogaster Larvae
07:26

Foraging Path-length Protocol for Drosophila melanogaster Larvae

Published on: April 23, 2016

9.9K

Area of Science:

  • Cardiovascular Regenerative Medicine
  • Cell-based Therapies
  • Regulatory Science

Background:

  • Despite promising clinical trial results, no cell-based therapy has gained regulatory approval for cardiovascular indications.
  • Significant barriers impede the path to regulatory approval for these advanced therapies.

Purpose of the Study:

  • To assess challenges hindering regulatory approval for cardiovascular cell-based therapies.
  • To identify strategies for facilitating the regulatory approval process.
  • To focus on treatments closest to achieving regulatory submission.

Main Methods:

  • Convened leaders from academia, industry, and regulatory bodies (FDA) at a symposium.
  • Focused discussion on barriers and potential solutions for cardiovascular regenerative medicine.
  • Considered treatments nearing regulatory approval stages.

Main Results:

  • Identified key barriers: manufacturing complexity, therapeutic challenges, comparator group selection, funding limitations, and demonstrating clinical efficacy.
  • Proposed strategies: cell therapy registry network for data sharing, standardized terminology, innovative statistical methods, functional endpoints, and utilizing the Regenerative Medicine Advanced Therapy designation.

Conclusions:

  • Overcoming regulatory hurdles requires collaborative efforts and innovative approaches.
  • Implementing proposed strategies can streamline the development and approval of cardiovascular cell therapies.
  • Early engagement with regulatory authorities is crucial for successful pathway planning.